Role of antimuscarinic medication in the treatment of antipsychoticinduced extrapyramidal effects
Antimuscarinic drugs are most effective for treating antipsychotic-induced Parkinsonism (ri gidity, bradykinesia and tremor) and dystonic reactions, including oculogyric crisis. Akathisia is unlikely to be helped by antimuscarinic medication, and tardive dyskinesia can be exacerbated by these drugs (Blaisdell, 1994; Ebel. 1994; Barnes & Phillips. 1996; Holloman & Marder, 1997) .
Antimuscarinic drugs should not be regarded as the mainstay for the treatment of antipsychoticinduced extrapyramidal movement disorders. The most reliable and effective treatment is to reduce the dose of the antipsychotic medication and, mental state permitting, maintain the patient on the lowest possible dose thereafter. An alterna tive is to substitute an atypical antipsychotic drug. Such drugs, which have fewer extrapyr amidal side-effects, may be useful for patients in whom conventional antipsychotics continue to cause troublesome extrapyramidal side-effects despite a reduction in antipsychotic dosage coupled with the addition of antimuscarinic medication. If the above measures fail and it proves necessary to prescribe antimuscarinic drugs, these should be used sparingly. Whenever possible, antimuscarinic drugs should be pre scribed on an 'as-required1 (p.r.n.) as opposed to a regular basis.
Prophylactic, regular and p.r.n. prescribing of antimuscarinic drugs
The prophylactic use of antimuscarinic medi cation for patients on long-term antipsychotic medication is not recommended (World Health Organization, 1990) . Antimuscarinic drugs have side-effects of their own and they exacerbate the antimuscarinic effects of antipsychotic drugs. When given regularly, in combination with antipsychotic medication, they can reduce the therapeutic activity of antipsychotic medication (Bamrah et al 1986) and predispose to the development of tardive dyskinesia (Barnes & Phillips, 1996) . Furthermore, antimuscarinic medication can cause an acute toxic state characterised by agitation and psychotic symp toms (Johnson et al, 1981) . Long-term use may be associated with memory impairment (Calev, 1984) , and antimuscarinic drugs may be mis used for their euphoriant properties (Pullen et al 1984 : Marken et al 1996 .
Regular antimuscarinic medication should not be given unless it is clear that without this the patient would continue to suffer from trouble some extrapyramidal symptoms. If the patient suffers only intermittently from extrapyramidal symptoms, 'as-required' antimuscarinics coupled with patient education may suffice. In circum stances where an antipsychotic depot prepara tion is being given on a regular basis, antimuscarinic medication may be required only for a few days after each dose of depot is given. Under these circumstances a limited p.r.n. supply can be dispensed.
Regulating the use of antimuscarinic medication
When antimuscarinics are used, the prescription should be reviewed on a regular basis. In many cases, extrapyramidal side-efTects associated with commencing or increasing the dose of antipsychotic medication are self-limiting and resolve within a matter of weeks (Barnes & Phillips, 1996) , therefore it is worthwhile attempt ing to reduce and discontinue antimuscarinics prescribed for newly emergent extrapyramidal disorders after a period of three months.
The instructions accompanying a p.r.n. prescription require accurate interpretation, and a working knowledge of antimuscarinic and antipsychotic drug properties is required if anti muscarinics are to be used only when indicated. Patients can receive considerable amounts of muscarinic medication via the 'as-required' route. Therefore, p.r.n. prescriptions should be moni tored as closely as prescriptions for antimuscari nics given on a regular basis. Educating patients about the side-effects of antipsychotic drugs and when to use 'as-required' doses of an anti muscarinic agent is also important. In addition, because nursing staff charged with the responsi bility of dispensing p.r.n. doses of antimuscarinic drugs are not always familiar with the indications and contraindications for giving this medication (Birmingham et aÃ¯, 1999) , it is worthwhile ensur ing that staff receive training on this subject and that guidelines are available for them to consult.
Education of doctors, psychiatric nursing staff and patients should help to reduce inappropriate prescribing and dispensing of p.r.n. anti muscarinic medication. However, it is also advisable for doctors and nurses to continually monitor their practice. The following guidelines can be used for this purpose: that is, for acute extrapyramidal effects. (d) Finally, before prescribing/dispensing, consider whether anything else should be taken into account with the patient, such as tendency to misuse substances.
In the longer term, it is important to monitor the patient's use of p.r.n. medication. If excessive quantities are being taken, this should be looked into. If significant amounts are being taken for genuine reasons, then other treatment avenues should be explored. Avoiding the use of antimuscarinic agents when they are not indicated and regulating their use when they are prescribed help to reduce the risk of patients developing unwanted, medicationrelated side-effects. This not only reduces un pleasant or stigmatising side-effects experienced by the patient but. with poor compliance being an issue for many patients taking antipsychotic drugs, steps taken to minimise unwanted medication-related effects may tip the balance in favour of compliance with treatment. 
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